';

Would you like to join our Early Access Programme?

It's essential to us that our technologies are quick, simple to use and make health workers' jobs easier.

We believe this is crucial in delivering diagnostic tools you can rely on.

QuantuMDx works with healthcare professionals from a range of settings to ensure our products fit seamlessly into clinical care pathways, and meet the needs of end users.

Our first commercial assay will detect and individually identify 14 high-risk human papillomavirus (HR-HPV) genotypes, providing a powerful diagnostic and surveillance tool for clinicians and public health officials alike.

In advance of commercialisation, we’re looking to collaborate with a small cohort of key partners to support our Q-POC™ clinical performance and utility testing programme.

We’re looking to engage with potential collaborators early, to be able to support you with business planning and/or grant applications.

If your healthcare organisation would like to collaborate with us, please email us directly at: moc.xdmutnauq@sseccaylrae

If you’d like to receive  regular updates about our work, please sign up for our e-newsletter.

SHARE THIS PAGE

Subscribe to our e-newsletter and keep up to date with QuantuMDx

THE FUTURE OF DIAGNOSTICS

Contact

Contact

Contact